Phthalic Anhydride

Phthalic Anhydride

SCHEMBL4436162

Nc1cccc(C(=O)O)c1.O=C1OC(=O)c2ccccc21

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PBRM1 Q86U86 1/20 0.56
ALOX15 P16050 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
HSD17B10 Q99714 1/20 0.46
TTR P02766 1/20 0.46
PTPRC P08575 2/20 0.45
KMO O15229 1/20 0.44
KMT2A Q03164 2/20 0.44
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA6 P23280 1/20 0.43
CA9 Q16790 1/20 0.43
POLB P06746 1/20 0.42
AKR1C3 P42330 1/20 0.42
DAO P14920 1/20 0.42
TSHR P16473 1/20 0.42
NAPRT Q6XQN6 1/20 0.42
TYMS P04818 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isophthalic Acid SCHEMBL4990367 0.88 TDP1 (0.56) ALOX15TDP1HSD17B10TTRPTPRC
SCHEMBL9181081 0.85 CA12 (0.49) PBRM1TDP1TTRPTPRCKMT2A
Terephthalic Acid SCHEMBL1292728 0.84 TTR (0.55) ALOX15TDP1HSD17B10TTRPTPRC
3-Aminobenzoic Acid SCHEMBL28231735 0.84 PBRM1 (0.70) PBRM1TDP1HSD17B10KMOKMT2A
3-Aminobenzoic Acid SCHEMBL29367812 0.84 PBRM1 (0.69) PBRM1HSD17B10KMOKMT2ACA12
3-Aminobenzoic Acid SCHEMBL27648 0.84 PBRM1 (0.69) PBRM1HSD17B10KMOKMT2ACA12
3-Aminobenzoic Acid SCHEMBL8003706 0.84 PBRM1 (0.69) PBRM1HSD17B10KMOKMT2ACA12
3-Aminobenzoic Acid SCHEMBL11796891 0.82 PBRM1 (0.67) PBRM1HSD17B10KMOKMT2ACA12
3-Aminobenzoic Acid SCHEMBL2296707 0.82 PBRM1 (0.67) PBRM1HSD17B10KMOKMT2ACA12
Phthalic Anhydride SCHEMBL5450495 0.82 TSHR (0.64) ALOX15TDP1HSD17B10TTRPTPRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8241371-B2 Concurrent precipitation of active material and crystal former from solution or suspension in presence of supercritical fluid such as carbon dioxide THAR PHARMACEUTICALS, INC. (US) 2012-08-14 US disclosed
EP-2117666-A1 METHOD OF CREATING CRYSTALLINE SUBSTANCES Thar Pharmaceuticals Inc. (US) 2009-11-18 EP disclosed
US-20080280858-A1 METHOD OF CREATING CRYSTALLINE SUBSTANCES THAR PHARMACEUTICALS, INC. (US) 2008-11-13 US disclosed
WO-2008096144-A1 METHOD OF CREATING CRYSTALLINE SUBSTANCES THAR PHARMACEUTICALS INC. (US) 2008-08-14 WO disclosed